High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer
β Scribed by J. T. Kamphuis; M. C. Huider; G. J. Ras; C. A. H. Verhagen; I. Kateman; J. H. A. Vreeswijk; J. T. M. Burghouts
- Book ID
- 104886898
- Publisher
- Springer
- Year
- 1995
- Tongue
- English
- Weight
- 265 KB
- Volume
- 37
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND: Small bowel adenocarcinoma (SBA) is a rare tumor with poor prognosis. Firstβline platinumβbased chemotherapy is active in patients with advanced SBA, but data regarding secondβline chemotherapy are lacking. The aim of this study was to evaluate the efficacy and tolerabil
Tenfour patients were treated with NFL: mitoxantrone 12 mg/m 2 IV on Day 1; leuconessee. vorin 300 mg IV over 30-60 minutes on Days 1, 2, and 3, immediately preceding
Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer
## BACKGROUND. Reports of in vitro experiments in colorectal carcinoma cells suggest that prolonged cellular exposure to 5-fluorouracil (5-FU) combined with relatively low concentrations of leucovorin (LV) provides optimal enhancement of 5-FU efficacy. In this study, a simplified regimen of weekly